PROTOKOLwiki
COMPOUNDS / CANNABINOID / THC
CANNABINOID

THC

MEDIUM RISK
BEST FOR:Pain●●●●●○○○○○5/10
THC · Δ9-THC · DELTA-9-TETRAHYDROCANNABINOL · TETRAHYDROCANNABINOL · DRONABINOL · MARINOL · SYNDROS
CannabinoidPsychoactiveAnalgesicCB1 AgonistCannabisControlled Substance

Primary psychoactive constituent of cannabis; partial agonist at CB1 and CB2 receptors with analgesic and intoxicating effects.

ROUTE / DOSAGE
LOW2.5mg
STANDARD5-10mg
HIGH25mg+
Note: Slow onset; effects can be intense due to 11-OH-THC first-pass metabolite
CYCLE
No established cycle tolerance develops with regular use
BIOAVAILABILITY
~10-35% oral ~50% inhaled ~15-45% sublingual
ACTIVE DURATION
2-8h (route-dependent) (subjective)
STORAGE
Room temperature dry away from light controlled substance storage per local regulations
HALF-LIFE
20-30h (terminal chronic use) 1-3h (alpha phase) (plasma)
DURATION BREAKDOWN
Total2-8h (route-dependent)
Onsetseconds-2h (route-dependent)
Come up5-60min (route-dependent)
Peak1-3h
Offset2-4h
After effects2-6h
Duration varies by route, dose, and individual. Source: community reports.
§ 01 — EFFECTS
8 documented
Euphoria and relaxation
Altered time perception
Increased appetite
Analgesia
Sedation
Impaired short-term memory
Motor incoordination
Anxiety or paranoia at higher doses
§ 02 — RISKS
Cannabis use disorder and dependence with regular use
Cognitive impairment and altered brain development with adolescent use
Increased risk of motor vehicle accidents
Psychiatric symptoms including anxiety, paranoia, and psychosis in susceptible individuals
Cardiovascular effects: tachycardia, orthostatic hypotension
Adverse drug interactions via CYP enzyme inhibition
§ 03 — INTERACTIONS
No interaction with your stack
VIEW STACK
CAUTION
2C-T-x
2C-x
5-MeO-xxT
Amphetamines
aMT
Cocaine
DMT
DOx
LSD
Mescaline
Mushrooms
25x-NBOMe
AVOID · DANGEROUS
Lithium
§ 04 — SCIENCE

THC has demonstrated moderate analgesic efficacy in neuropathic pain, with a 2025 systematic review finding small improvements for high THC-to-CBD ratio products. Nabilone reduced pain severity but dronabinol did not reach significance in pooled analysis. THC shows synergistic anti-allodynic effects with gabapentin in preclinical models, improving therapeutic window. Pharmacokinetics are heavily route-dependent, with oral bioavailability limited by first-pass metabolism and high inter-individual variability driven by CYP2C9 polymorphisms. Evidence for long-term safety and efficacy remains limited, and adverse events including dizziness, sedation, and nausea are common.

§ 06 — SOURCES
[1]
Review of delta-8-THC: Comparative pharmacology with Δ9-THC (PMID 35523678)
pubmed.ncbi.nlm.nih.gov ↗
[2]
THC-O-Acetate: Scarce Evidence for a Psychedelic Cannabinoid (PMID 37381980)
pubmed.ncbi.nlm.nih.gov ↗
[3]
THC shows activity against cultured Plasmodium falciparum (PMID 34763083)
pubmed.ncbi.nlm.nih.gov ↗
[4]
Administration of Δ9-THC in Adolescent and Adult Mice (PMID 40824853)
pubmed.ncbi.nlm.nih.gov ↗
[5]
Toxicogenetic analysis of Δ9-THC-metabolizing enzymes (PMID 32712703)
pubmed.ncbi.nlm.nih.gov ↗
[6]
THC and gabapentin interactions in a mouse neuropathic pain model (PMID 30312630)
pubmed.ncbi.nlm.nih.gov ↗
[7]
Δ9-THC isomers pharmacology, toxicology and analysis (PMID 35985136)
pubmed.ncbi.nlm.nih.gov ↗
[8]
Cannabis-Based Products for Chronic Pain: Updated Systematic Review (PMID 41429020)
pubmed.ncbi.nlm.nih.gov ↗
[9]
PsychonautWiki - Cannabis
psychonautwiki.org ↗
Disclaimer. Protokol.wiki is an informational reference. Nothing on this site is medical advice. Compounds listed may be unapproved, unregulated, or illegal in your jurisdiction. Consult a licensed physician before use. Data compiled from peer-reviewed literature.
METHODOLOGYCONTRIBUTECONTACT